Showing results (251-260 of 389) with videos related to
Sort By:
Pageof 39
Japanese Journal of Clinical Oncology|March 27, 2024
Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groupsKenichi Nakamura, Koji Takeda, Akiko M Saito, et al.Cancer Science|April 24, 2003
Expression of constitutively activated EGFRvIII in non-small cell lung cancerIsamu Okamoto, Lawrence C Kenyon, David R Emlet, et al.Anticancer Research|October 3, 2018
PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung CancerShinkichi Takamori, Kazuki Takada, Gouji Toyokawa, et al.Oncotarget|October 6, 2017
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring <i>EGFR</i> mutationsKentaro Tanaka, Kaname Nosaki, Kohei Otsubo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 10, 2014
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancerIsamu Okamoto, Masaki Miyazaki, Masayuki Takeda, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial PneumonitisSatoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu, et al.BMC Cancer|May 3, 2020
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, et al.Cancer Research|February 11, 2010
FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growthHiroyasu Kaneda, Tokuzo Arao, Kaoru Tanaka, et al.ESMO Open|November 16, 2016
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinibKoichi Azuma, Tomonori Hirashima, Nobuyuki Yamamoto, et al.Journal of Cancer Research and Clinical Oncology|May 15, 2020
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtypeKazuki Takada, Gouji Toyokawa, Fumihiko Kinoshita, et al.Pageof 39